Learn about hypertrophic cardiomyopathy, the leading cause of sudden cardiac death in young athletes. Understand the symptoms ...

In one of two trials with myosin inhibitors for hypertrophic cardiomyopathy, one showed effectiveness for the obstructive type, while the other fell flat against the non-obstructive form.

Among patients with nonobstructive hypertrophic cardiomyopathy, mavacamten did not improve peak oxygen uptake or decrease ...

In patients with obstructive hypertrophic cardiomyopathy, the cardiac myosin inhibitor aficamten was superior to the beta-blocker metoprolol for improving symptoms and peak oxygen uptake, according to ...

Mavacamten treatment at 48 weeks was not associated with significant improvements in patient-reported health status or peak ...

Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics ...

A Spanish study shows that patients with genetic dilated cardiomyopathy who experience severe arrhythmias are at an elevated ...

PARAMUS, N.J., March 10, 2025 /PRNewswire/ -- NS Pharma, Inc. (NS Pharma), a subsidiary of Nippon Shinyaku Co., Ltd. (Nippon Shinyaku), announced today that ...